Abstract: The use of a medicament as a single agent, binary agent, or other combination comprising of substantially pure novel cannabinoids 1 and 2, optionally admixed with one or more known and novel cannabinoids and other known naturally occurring and synthetic tetracyclic 2A and tricyclic 1A cannabinoids for the prevention, treatment or cure of inflammatory mediated diseases or inflammatory mediated pathological conditions, anorexia, arthritis, cancer, pain, glaucoma, migraine, persistent muscle spasms, seizures (epileptic seizures), severe nausea, PTSD, autism spectrum disorder, drug abuse, insomnia, or any other chronic or persistent medical symptom.

Abstract: The present invention relates to a process for the preparation of diverse known and novel cannabinoids 5, which include cannabigerol (CBG, 1), cannabigerolic acid (CBGA, 2), cannabigerovarin (CBGV, 3), cannabigerovarinic acid (CBGVA, 4) and other naturally occurring monocyclic cannabinoids and other analogues from simple inexpensive starting materials using a cascade sequence of allylic rearrangement and aromatization. Novel cannabinoids of series 5 are also claimed as part of the invention. These synthesized cannabinoids, unlike the minor cannabinoids isolated from Cannabis saliva or synthesized from the condensation reactions such as the reactions of substituted resorcinols with monoterpenes, are much easier to obtain at high purity levels. In particular, these cannabinoids, including but not limited to cannabigerol (CBG, 1), cannabigerolic acid (CBGA, 2), cannabigerovarin (CBGV, 3) and cannabigerovarinic acid (CBGVA, 4) are obtained without contamination with impurities with variation in RA and RB (e.g.

Abstract: A process for the preparation of diverse known and novel cannabinoids (5), which include cannabinol (CBN, 1), cannabinolic acid (CBNA, 2), cannabivarin (CBV, 3) and cannabivarinic acid (CBVA, 4) and other naturally occurring monocyclic and tricyclic cannabinoids and other analogues from simple inexpensive starting materials using a cascade sequence of allylic rearrangement, aromatization and, as appropriate, further highly selective cyclization reactions. Additionally, cannabinoids of the formula (5) and intermediates of the formula (9) form part of the invention. Use of medicaments comprising one or more of the disclosed cannabinoids alone or admixed with one or more other cannabinoids is also disclosed.

Abstract: The present invention relates to intermediate compounds for the synthesis of novel cannabinoids 1 and 2, synthesized from simple starting materials using a cascade sequence of allylic rearrangement, aromatization and, for tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2 are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol. The analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis oil. Novel compounds of the formulas 3 and 6, useful as intermediates for the synthesis of the cannabinoids of advanced intermediates 4 and 5 as well as cannabinoids of the formulas 1 and 2, are disclosed.

Abstract: The present invention relates to intermediate compounds for the synthesis of novel cannabinoids 1 and 2, synthesized from simple starting materials using a cascade sequence of allylic rearrangement, aromatization and, for tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2 are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol. The analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis oil. Novel compounds of the formulas 3 and 6, useful as intermediates for the synthesis of the cannabinoids of advanced intermediates 4 and 5 as well as cannabinoids of the formulas 1 and 2, are disclosed.

Abstract: A process for the preparation of substantially pure diverse known and novel cannabinoids 1 and 2, which include ?9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), cannabidiol (11), cannabidivarin (12) and other naturally occurring tetracyclic and tricyclic cannabinoids and other synthetic tetracyclic and tricyclic analogues, via intermediates 3, 6, 4 and 5, using a cascade sequence of allylic rearrangement, aromatization and, for the tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2, including ?9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol.

Abstract: The present invention relates to novel cannabinoids 1 and 2, synthesized from simple starting materials using a cascade sequence of allylic rearrangement, aromatization and, for tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2 are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol. The analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis oil. Novel compounds of the formulas 3, 4, 5 and 6, as intermediates for the synthesis of the cannabinoids of the formulas 1 and 2 are also disclosed.

Abstract: Embodiments of a tamper-evident closure are disclosed which prevent unauthorized access to a container and its contents, deterring adulteration or introduction of counterfeit product. In one embodiment the tamper-evident closure can be fitted to an associated container and closure, and includes a portion which is removed by fracture of the tamper-evident closure to gain access to the container closure. In another embodiment, an arrangement of wedge-like tongues permit fitment of the tamper-evident closure to associated container for temper-evidence. In another embodiment, the tamper-evident closure is joined by frangible bridges to the container closure to provide the desired tamper-evidence. In another embodiment, the tamper-evident closure is movable axially of the associated container closure to thereby provide evidence of removal.

Abstract: The use of a medicament as a single agent, binary agent, or other combination comprising of substantially pure novel cannabinoids 1 and 2, optionally admixed with one or more known and novel cannabinoids and other known naturally occurring and synthetic tetracyclic 2A and tricyclic 1A cannabinoids for the prevention, treatment or cure of inflammatory mediated diseases or inflammatory mediated pathological conditions, anorexia, arthritis, cancer, pain, glaucoma, migraine, persistent muscle spasms, seizures (epileptic seizures), severe nausea, PTSD, autism spectrum disorder, drug abuse, insomnia, or any other chronic or persistent medical symptom.

Abstract: The present invention relates to novel cannabinoids 1 and 2, synthesized from simple starting materials using a cascade sequence of allylic rearrangement, aromatization and, for tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2 are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol. The analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components of cannabis oil. Novel compounds of the formulas 3, 4, 5 and 6, as intermediates for the synthesis of the cannabinoids of the formulas 1 and 2 are also disclosed.

Abstract: A process for the preparation of substantially pure diverse known and novel cannabinoids 1 and 2, which include ?9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), cannabidiol (11), cannabidivarin (12) and other naturally occurring tetracyclic and tricyclic cannabinoids and other synthetic tetracyclic and tricyclic analogues, via intermediates 3, 6, 4 and 5, using a cascade sequence of allylic rearrangement, aromatization and, for the tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2, including ?9-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), are obtained containing very low levels of isomeric cannabinoids such as the undesirable ?8-tetrahydrocannabinol.

Abstract: An anti-refill closure assembly comprises a closure body having an upper spout portion and a lower fitment portion configured for securement to an associated container. The closure body defines at least one flow passage through which liquid from the container enters the closure body. A reciprocable valve member is positioned within the closure body for movement between opened and closed positions. In the opened position of the valve member, liquid from within the container flows into the closure body through the at least one flow passage, and past the valve member outwardly through the upper spout portion. In the closed position of the valve member, the valve member acts to prevent the reverse flow of liquid from the outer spout portion back through the valve body and into the associated container.

Abstract: Embodiments of a tamper-evident closure are disclosed which prevent unauthorized access to a container and its contents, deterring adulteration or introduction of counterfeit product. In one embodiment the tamper-evident closure can be fitted to an associated container and closure, and includes a portion which is removed by fracture of the tamper-evident closure to gain access to the container closure. In another embodiment, an arrangement of wedge-like tongues permit fitment of the tamper-evident closure to associated container for temper-evidence. In another embodiment, the tamper-evident closure is joined by frangible bridges to the container closure to provide the desired tamper-evidence. In another embodiment, the tamper-evident closure is movable axially of the associated container closure to thereby provide evidence of removal.

Abstract: An anti-refill closure assembly comprises a closure body having an upper spout portion and a lower fitment portion configured for securement to an associated container. The closure body defines at least one flow passage through which liquid from the container enters the closure body. A reciprocable valve member is positioned within the closure body for movement between opened and closed positions. In the opened position of the valve member, liquid from within the container flows into the closure body through the at least one flow passage, and past the valve member outwardly through the upper spout portion. In the closed position of the valve member, the valve member acts to prevent the reverse flow of liquid from the outer spout portion back through the valve body and into the associated container.

Abstract: A plastic closure includes a top wall portion, and an annular depending skirt portion having at least one internal thread formation. In order to facilitate high-speed closure application to an associated container, the closure includes an application guide feature positioned in circumferentially spaced relationship to a thread start of the internal thread formation of the closure. The application guide feature is configured to engage the lower surface of an external thread formation of the associated container, whereby cocking, tilting, and other misalignment of the closure is avoided as it is applied to the container with high-speed application equipment.

Abstract: A closure and container package for pressurized products, such as carbonated beverages, includes a closure comprising a closure cap having a top wall portion, and an annular skirt portion depending from the top wall portion. Features of the closure construction, and selection of the polymer from which the closure is formed, permits the closure to meet sealing, impact resistance, and other performance criteria, with desirably reduced use of polymeric material. Significant cost savings can thus be achieved.

Abstract: A plastic closure includes a top wall portion, and an annular depending skirt portion having at least one internal thread formation. In order to facilitate high-speed closure application to an associated container, the closure includes an application guide feature positioned in circumferentially spaced relationship to a thread start of the internal thread formation of the closure. The application guide feature is configured to engage the lower surface of an external thread formation of the associated container, whereby cocking, tilting, and other misalignment of the closure is avoided as it is applied to the container with high-speed application equipment.

Abstract: Chaps, such as riding chaps and, in particular, protective chaps intended to be worn by farriers and those conducting similar work, and frequently referred to as “aprons”, with improved support and/or comfort, particularly in the lumbar or sacroiliac region. The chaps have an integral belt region, extending around the front of a wearer. The belt region has extension pieces, at either end, for the attachment of a linking belt portion which is intended to pass around the back of the wearer and thus complete the belt. The linking belt portion bears an enlargement providing a lumbar support and/or a posture aid for the wearer. The attachment of the linking belt portion to the extension pieces can be accomplished by fitments which allow for quick release/engagement and/or adjustment of the belt as a whole.

Abstract: A selectively loadable/sealable bioresorbable carrier assembly for retaining and positioning elements used in brachytherapy procedures comprises a bioresorbable tube having a closed distal end and a proximal open end. The bioresorbable tube is loaded with a selectable arrangement of elements, including at least one radioactive seed, through the proximal open end. After the bioresorbable tube is selectably loaded, the bioresorbable tube is heat sealed at a sealing position adjacent a proximalmost element. Once sealed, the bioresorbable tube maintains the arrangement of elements throughout the treatment duration.

Abstract: A hinged electronic device (100) includes housing hinge mechanism (130) holding together a first housing section (110) with a first screen portion (160) of a hinged screen (150) and a second housing section (120) with a recess (184) for a second screen portion (170) of the hinged screen (150). The first screen portion (160) and the second screen portion (170) are held together by a screen hinge mechanism (480). When the hinged electronic device (100) is closed, the hinged screen (150) is in a stowed position. When the hinged electronic device (100) is fully opened, the hinged screen (150) is in a fully deployed position, which has the first screen portion (160) and the second screen portion (170) within a single plane.